Iperion HY25: still zero revenue with cash at $0.087m and equity down 62%

What changed

Iperion remained pre-revenue, with $0 of sales in HY25 as in HY24 and FY24. The reported loss narrowed: PBT and NPAT were identical at $(0.364)m versus $(0.463)m, an improvement of 21.4%. Operating cash outflow eased to $(0.268)m from $(0.371)m (27.8% lower), and capex stayed negligible at $0.003m, giving an estimated pre-lease free cash outflow of $(0.271)m versus $(0.380)m. The balance sheet, however, deteriorated sharply: total assets fell 50.9% to $0.620m, total equity fell 62.2% to $0.440m, and the calculation pass shows cash at $0.087m versus $0.169m at FY24. Total liabilities rose 80% to $0.180m off a small base. No dividend was declared.

What matters

• Runway, not the loss line. A $0.087m cash position against a roughly $0.27m half-year cash burn is the dominant fact in this release. The narrower loss is essentially irrelevant if the company cannot fund the next operating cycle without additional capital.
• Equity erosion outpaced the P&L loss. Equity dropped $0.724m while the period loss was $0.364m, implying material other movements through equity reducing the carrying base; ROE worsened to -82.6% from -39.8% on a much smaller capital base.
• Strategy still stuck at pre-commercialisation. The release language continues to point to certifications and the move into commercial production and sales, with the only revenue hook being minimum royalty performance targets in an antimicrobial license agreement. Nothing in the filing demonstrates that step has begun.

Expectations

No quantitative guidance, forward-work value, or stated target was disclosed, so there is no formal benchmark to test the result against. There is also no useful seasonality or shape context: the FY24 anchor itself recorded $0 revenue and an $(0.812)m full-year loss, against which HY24 NPAT of $(0.463)m represented 57% of the full-year loss and HY24 operating outflow 51.2%. On that crude pattern, an unchanged second-half cadence would imply a full-year loss broadly in line with FY24, but that says nothing about commercial traction. The release does not support any read on when revenue begins.

Quality of result

The improvement is genuine in direction but trivial in magnitude and entirely cost-driven, since revenue is zero. Tax did not distort the result — income tax was nil in both periods, so PBT and NPAT moved together. Cash conversion is not the right lens for a pre-revenue issuer; the relevant point is that the smaller operating outflow still consumed a disproportionate share of the opening cash, and the equity decline of $0.724m far exceeds the P&L loss, indicating the half consumed more of the capital base than the income statement alone shows. There is no working-capital, segment, or non-recurring detail to suggest the improvement is anything other than lower spend.

Unresolved

• How is the company funded from here, given $0.087m of cash against a half-year burn near $0.27m? The filing does not disclose a capital plan, facility, or commitment.
• What reconciles the $0.724m equity reduction to the $0.364m reported loss — share movements, reserves, or other adjustments are not visible in the supplied excerpts.
• What revenue, if any, is contractually triggered by the antimicrobial license minimum performance targets, and over what timeframe?
• When does management expect first commercial sales, and what certifications remain outstanding?

This briefing cannot assess solvency, going-concern status, or the terms of any capital-raising or licensing arrangements beyond what the supplied excerpts state.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.